Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G0BL
|
|||
| Former ID |
DNCL002364
|
|||
| Drug Name |
AMG 337
|
|||
| Indication | Clear cell sarcoma [ICD-11: 2A60-2C35] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22FN7O3
|
|||
| Canonical SMILES |
CC(C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC
|
|||
| InChI |
1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
|
|||
| InChIKey |
DWHXUGDWKAIASB-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 1173699-31-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | J Clin Oncol 32:5s, 2014 (suppl; abstr 2508). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.